Generic Trintellix Availability

Last updated on Jul 9, 2025.

Trintellix is a brand name of vortioxetine, approved by the FDA in the following formulation(s):

TRINTELLIX (vortioxetine hydrobromide - tablet;oral)

• Manufacturer: TAKEDA PHARMS USA
  Approval date: September 30, 2013
  Strength(s): EQ 5MG BASE ^[RLD], EQ 10MG BASE ^[RLD], EQ 15MG BASE (discontinued) ^[RLD], EQ 20MG BASE ^[RLD]

Is there a generic version of Trintellix available?

No. There is currently no therapeutically equivalent version of Trintellix available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trintellix. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
  Patent 11,458,134
  Issued: October 4, 2022
  Inventor(s): Faldt André & Lopez de Diego Heidi & Holm Rene & Mealy Michael J.
  Assignee(s): H. Lundbeck A/S
  

  1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HTand 5-HTand may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

  Patent expiration dates:

  • June 15, 2027
    
    ✓ 
    Patent use: USE OF TRINTELLIX FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN ADULTS
    ✓ 
    Drug product
• 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
  Patent 11458134*PE
  Issued: October 4, 2022
  Inventor(s): Faldt André & Lopez de Diego Heidi & Holm Rene & Mealy Michael J.
  Assignee(s): H. Lundbeck A/S
  

  1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HTand 5-HTand may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

  Patent expiration dates:

  • December 15, 2027
    
• Phenyl-piperazine derivatives as serotonin reuptake inhibitors
  Patent 7,144,884
  Issued: December 5, 2006
  Inventor(s): Ruhland; Thomas et al.
  Assignee(s): H. Lundbeck A/S (Copenhagen-Valby, DK)
  

  The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder ##STR00001##

  Patent expiration dates:

  • June 17, 2026
    
    ✓ 
    Patent use: METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Phenyl-piperazine derivatives as serotonin reuptake inhibitors
  Patent 7144884*PED
  Issued: December 5, 2006
  Inventor(s): Ruhland; Thomas et al.
  Assignee(s): H. Lundbeck A/S (Copenhagen-Valby, DK)
  

  The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder ##STR00001##

  Patent expiration dates:

  • December 17, 2026
    
    ✓ 
    Pediatric exclusivity
• 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
  Patent 8,722,684
  Issued: May 13, 2014
  Inventor(s): Bang-Andersen Benny & Faldt Andre & Mork Arne & Lopez de Diego Heidi & Holm Rene & Stensbol Tine Bryan & Moore Nicholas
  Assignee(s): H. Lundbeck A/S
  

  1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HTand 5-HTand may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

  Patent expiration dates:

  • June 30, 2031
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
  Patent 8722684*PED
  Issued: May 13, 2014
  Inventor(s): Bang-Andersen Benny & Faldt Andre & Mork Arne & Lopez de Diego Heidi & Holm Rene & Stensbol Tine Bryan & Moore Nicholas
  Assignee(s): H. Lundbeck A/S
  

  1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HTand 5-HTand may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

  Patent expiration dates:

  • December 30, 2031
    
    ✓ 
    Pediatric exclusivity
• 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
  Patent 8,969,355
  Issued: March 3, 2015
  Inventor(s): Bang-Andersen Benny & Faldt Andre & Holm Rene & de Diego Heidi Lopez
  Assignee(s): H. Lundbeck A/S
  

  This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

  Patent expiration dates:

  • June 15, 2027
    
    ✓ 
    Patent use: METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
• 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
  Patent 8969355*PED
  Issued: March 3, 2015
  Inventor(s): Bang-Andersen Benny & Faldt Andre & Holm Rene & de Diego Heidi Lopez
  Assignee(s): H. Lundbeck A/S
  

  This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

  Patent expiration dates:

  • December 15, 2027
    
    ✓ 
    Pediatric exclusivity
• 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HTand 5-HTactivity for the treatment of cognitive impairment
  Patent 9,125,908
  Issued: September 8, 2015
  Inventor(s): Bang-Andersen Benny & Mork Arne & Stensbol Tine Bryan & Faldt Andre & Holm Rene & de Diego Heidi Lopez
  Assignee(s): H. Lundbeck A/S
  

  1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HTand 5-HTand may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

  Patent expiration dates:

  • June 15, 2027
    
    ✓ 
    Patent use: USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
• 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HTand 5-HTactivity for the treatment of cognitive impairment
  Patent 9125908*PED
  Issued: September 8, 2015
  Inventor(s): Bang-Andersen Benny & Mork Arne & Stensbol Tine Bryan & Faldt Andre & Holm Rene & de Diego Heidi Lopez
  Assignee(s): H. Lundbeck A/S
  

  1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HTand 5-HTand may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

  Patent expiration dates:

  • December 15, 2027
    
    ✓ 
    Pediatric exclusivity
• 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HTand 5-HTactivity for the treatment of cognitive impairment
  Patent 9,125,909
  Issued: September 8, 2015
  Inventor(s): Bang-Andersen Benny & Faldt Andre & Mork Arne & de Diego Heidi Lopez & Holm Rene & Stensbol Tine Bryan
  Assignee(s): H. Lundbeck A/S
  

  This disclosure relates to 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof in a crystalline form.

  Patent expiration dates:

  • June 15, 2027
    
    ✓ 
    Patent use: USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
• 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HTand 5-HTactivity for the treatment of cognitive impairment
  Patent 9125909*PED
  Issued: September 8, 2015
  Inventor(s): Bang-Andersen Benny & Faldt Andre & Mork Arne & de Diego Heidi Lopez & Holm Rene & Stensbol Tine Bryan
  Assignee(s): H. Lundbeck A/S
  

  This disclosure relates to 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof in a crystalline form.

  Patent expiration dates:

  • December 15, 2027
    
    ✓ 
    Pediatric exclusivity
• 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HTand 5-HTactivity for the treatment of cognitive impairment
  Patent 9,125,910
  Issued: September 8, 2015
  Inventor(s): Bang-Andersen Benny & Mork Arne & Stensbol Tine Bryan & Faldt Andre
  Assignee(s): H. Lundbeck A/S
  

  This disclosure relates to a method of treating a disease selected from the group consisting of Alzheimer's disease, cognitive impairment, and attention deficit hyperactivity disorder (ADHD). The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

  Patent expiration dates:

  • June 15, 2027
    
    ✓ 
    Patent use: USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
• 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HTand 5-HTactivity for the treatment of cognitive impairment
  Patent 9125910*PED
  Issued: September 8, 2015
  Inventor(s): Bang-Andersen Benny & Mork Arne & Stensbol Tine Bryan & Faldt Andre
  Assignee(s): H. Lundbeck A/S
  

  This disclosure relates to a method of treating a disease selected from the group consisting of Alzheimer's disease, cognitive impairment, and attention deficit hyperactivity disorder (ADHD). The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

  Patent expiration dates:

  • December 15, 2027
    
    ✓ 
    Pediatric exclusivity
• 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
  Patent 9,227,946
  Issued: January 5, 2016
  Inventor(s): Faldt Andre & Holm Rene & de Diego Heidi Lopez
  Assignee(s): H. Lundbeck A/S
  

  1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HTand 5-HTand may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

  Patent expiration dates:

  • June 15, 2027
    
    ✓ 
    Patent use: METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
• 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
  Patent 9227946*PED
  Issued: January 5, 2016
  Inventor(s): Faldt Andre & Holm Rene & de Diego Heidi Lopez
  Assignee(s): H. Lundbeck A/S
  

  1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HTand 5-HTand may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

  Patent expiration dates:

  • December 15, 2027
    
    ✓ 
    Pediatric exclusivity
• Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
  Patent 9,278,096
  Issued: March 8, 2016
  Inventor(s): Dragheim; Marianne
  Assignee(s): H. Lundbeck A/S (Valby, DK); Takeda Pharmaceuticals North America, Inc. (Deerfield, IL)
  

  New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.

  Patent expiration dates:

  • March 21, 2032
    
    ✓ 
    Patent use: USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT
• Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
  Patent 9278096*PED
  Issued: March 8, 2016
  Inventor(s): Dragheim; Marianne
  Assignee(s): H. Lundbeck A/S (Valby, DK); Takeda Pharmaceuticals North America, Inc. (Deerfield, IL)
  

  New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.

  Patent expiration dates:

  • September 21, 2032
    
    ✓ 
    Pediatric exclusivity
• 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HTand 5-HTactivity for the treatment of cognitive impairment
  Patent 9,861,630
  Issued: January 9, 2018
  Inventor(s): Faldt André & Lopez de Diego Heidi & Holm Rene
  Assignee(s): H. Lundbeck A/S
  

  1-[2-(2,4-dimethylphenylsulphanyl)phenyl)]piperazine exhibits potent activity on SERT, 5-HTand 5-HTand may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

  Patent expiration dates:

  • June 15, 2027
    
    ✓ 
    Patent use: METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
• 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HTand 5-HTactivity for the treatment of cognitive impairment
  Patent 9861630*PED
  Issued: January 9, 2018
  Inventor(s): Faldt André & Lopez de Diego Heidi & Holm Rene
  Assignee(s): H. Lundbeck A/S
  

  1-[2-(2,4-dimethylphenylsulphanyl)phenyl)]piperazine exhibits potent activity on SERT, 5-HTand 5-HTand may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

  Patent expiration dates:

  • December 15, 2027
    
    ✓ 
    Pediatric exclusivity

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • August 23, 2026 - INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
  • February 23, 2027 - PEDIATRIC EXCLUSIVITY

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer